|
1
|
Ljungberg B, Hanbury DC, Kuczyk MA,
Merseburger AS, et al: Guía del carcinoma de células renales. Actas
Urológicas Españolas. 33:270–279. 2004.(In Spanish).
|
|
2
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality
Worldwide. IARC CancerBase no. 11. International Agency for
Research on Cancer; Lyon: 2013, http://globocan.iarc.fr.
Accessed April 22, 2012
|
|
3
|
Gobierno del Principado de Asturias.
Mortalidad en Asturias. 2009, http://www.asturias.es/Astursalud/Ficheros/AS_Salud%20Publica/AS_Salud%20Poblacional/IS_Registro%20de%20mortalidad/mortalidad%20en%20Asturias%202009.pdf.
(In Spanish). Accessed August 6, 2012
|
|
4
|
Servicio de Salud del Principado de
Asturias. Registro hospitalario de tumores del Servicio de Salud
del Principado de Asturias. http://www.asturias.es/Astursalud/Ficheros/AS_SESPA/Memoria%20Rehotusespa%202009.pdf.
(In Spanish). Accessed August 8, 2012
|
|
5
|
Chow WH, Gridley G, Fraumeni JF Jr and
Järvholm B: Obesity, hypertension, and the risk of kidney cancer in
men. N Engl J Med. 343:1305–1311. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cohen HT and McGovern FJ: Renal-cell
carcinoma. N Engl J Med. 353:2477–2490. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aguiló M, Alba F, Ballester M, et al:
Carcinoma de las células renales. The Pharmaceutical letter. 9:pp.
85922007, (In Spanish) http://server.diaz-caneja-consultores.com/dicaf/site-v2/files/pharmaceuticalletter/The_Pharma_Letter_n10-2007.pdf.
Accessed July 10, 2014
|
|
8
|
Motzer RJ, Bacik J, Murphy BA, Russo P and
Mazumdar M: Interferon-alfa as a comparative treatment for clinical
trials of new therapies against advanced renal cell carcinoma. J
Clin Oncol. 20:289–296. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Escudier B and Kataja V; ESMO Guidelines
Working Group. Renal cell carcinoma: ESMO Clinical Practice
Guidelines for diagnosis, treatment and follow-up. Ann Oncol.
21(Suppl 5): v137–v139. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Mekhail TM, Abou-Jawde RM, Boumerhi G, et
al: Validation and extension of the Memorial Sloan-Kettering
prognostic factors model for survival in patients with previously
untreated metastatic renal cell carcinoma. J Clin Oncol.
23:832–841. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hudes G, Carducci M, Tomczak P, et al;
Global ARCC Trial. Temsirolimus, interferon alfa, or both for
advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007.
View Article : Google Scholar
|
|
12
|
Heng DY, Xie W, Regan MM, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar
|
|
13
|
Patil S, Figlin RA, Hutson TE, et al:
Prognostic factors for progression-free and overall survival with
sunitinib targeted therapy and with cytokine as first-line therapy
in patients with metastatic renal cell carcinoma. Ann Oncol.
22:295–300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Sunitinib versus interferon alfa in metastatic renal-cell
carcinoma. N Engl J Med. 356:115–124. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gore ME, Szczylik C, Porta C, et al:
Safety and efficacy of sunitinib for metastatic renal-cell
carcinoma: an expanded-access trial. Lancet Oncol. 10:757–763.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun M, Lughezzani G, Perrotte P and
Karakiewicz PI: Treatment of metastatic renal cell carcinoma. Nat
Rev Urol. 7:327–338. 2010. View Article : Google Scholar
|
|
17
|
Hutson TE: Targeted therapies for the
treatment of metastatic renal cell carcinoma: clinical evidence.
Oncologist. 16(Suppl 2): 14–22. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Motzer RJ, Hutson TE, Tomczak P, et al:
Overall survival and updated results for sunitinib compared with
interferon alfa in patients with metastatic renal cell carcinoma. J
Clin Oncol. 27:3584–3590. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kidney Cancer. NCCN Clinical Practice
Guidelines in Oncology. Version 3.2014 http://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf.
Accessed March 22, 2014
|
|
20
|
Lee WK, Byun SS, Kim HH, Rha KH, Hwang TK,
Sung GT, et al: Characteristics and prognosis of chromophobe
non-metastatic renal cell carcinoma: a multicenter study. Int J
Urol. 17:898–904. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Molina AM, Feldman DR, Ginsberg MS, et al:
Phase II trial of sunitinib in patients with metastatic non-clear
cell renal cell carcinoma. Invest New Drugs. 30:335–340. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Motzer RJ, Mazumdar M, Bacik J, Berg W,
Amsterdam A and Ferrara J: Survival and prognostic stratification
of 670 patients with advanced renal cell carcinoma. J Clin Oncol.
17:2530–2540. 1999.PubMed/NCBI
|
